Free Trial

Biogen (BIIB) Stock Forecast & Price Target

Biogen logo
$144.86 -3.98 (-2.67%)
Closing price 09/12/2025 04:00 PM Eastern
Extended Trading
$145.26 +0.40 (+0.28%)
As of 09/12/2025 07:36 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Biogen - Analysts' Recommendations and Stock Price Forecast (2025)

Consensus Rating

Sell
0
Hold
21
Buy
10

Based on 31 Wall Street analysts who have issued ratings for Biogen in the last 12 months, the stock has a consensus rating of "Hold." Out of the 31 analysts, 21 have given a hold rating, and 10 have given a buy rating for BIIB.

Consensus Price Target

$181.65
25.40% Upside
According to the 31 analysts' twelve-month price targets for Biogen, the average price target is $181.65. The highest price target for BIIB is $275.00, while the lowest price target for BIIB is $118.00. The average price target represents a forecasted upside of 25.40% from the current price of $144.86.
MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
Get the Latest News and Ratings for BIIB and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Biogen and its competitors.

Sign Up
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

BIIB Analyst Ratings Over Time

TypeCurrent Forecast
9/13/24 to 9/13/25
1 Month Ago
8/14/24 to 8/14/25
3 Months Ago
6/15/24 to 6/15/25
1 Year Ago
9/14/23 to 9/13/24
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
10 Buy rating(s)
11 Buy rating(s)
12 Buy rating(s)
17 Buy rating(s)
Hold
21 Hold rating(s)
21 Hold rating(s)
20 Hold rating(s)
8 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$181.65$185.63$188.19$275.52
Forecasted Upside25.40% Upside37.56% Upside44.04% Upside40.84% Upside
Consensus RatingHoldHoldHoldModerate Buy

BIIB Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

BIIB Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Biogen Stock vs. The Competition

TypeBiogenMedical CompaniesS&P 500
Consensus Rating Score
2.32
2.78
2.53
Consensus RatingHoldModerate BuyModerate Buy
Predicted Upside24.79% Upside17,329.38% Upside10.47% Upside
News Sentiment Rating
Positive News

See Recent BIIB News
Positive News
Positive News
DateBrokerageAnalystActionRatingPrice TargetReport Date
Upside/Downside
Details
9/4/2025Needham & Company LLC
2 of 5 stars
Ami Fadia
Ami Fadia
5 of 5 stars
Reiterated RatingHold
8/14/2025Piper Sandler
2 of 5 stars
David Amsellem
David Amsellem
Not Rated
Boost TargetNeutral$115.00 ➝ $118.00-11.71%
8/1/2025Citigroup
2 of 5 stars
Geoff Meacham
Geoff Meacham
Not Rated
Boost TargetNeutral$125.00 ➝ $135.00+2.31%
8/1/2025Royal Bank Of Canada
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost TargetOutperform$208.00 ➝ $219.00+73.42%
8/1/2025Morgan Stanley
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower TargetEqual Weight$146.00 ➝ $144.00+15.25%
8/1/2025HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost TargetBuy$187.00 ➝ $194.00+51.56%
7/21/2025Truist Financial
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Initiated CoverageHold$142.00+14.61%
6/12/2025Wedbush
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingNeutral$121.00-8.77%
5/7/2025Mizuho
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower TargetOutperform$207.00 ➝ $169.00+44.55%
5/5/2025JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower TargetNeutral$185.00 ➝ $175.00+42.11%
5/2/2025Oppenheimer
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Target$205.00+68.31%
5/2/2025Canaccord Genuity Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower TargetBuy$265.00 ➝ $220.00+78.51%
5/2/2025Robert W. Baird
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower TargetOutperform$300.00 ➝ $255.00+110.87%
4/28/2025HSBC
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 DowngradeBuyHold$118.00-0.71%
4/28/2025Hsbc Global Res
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeStrong-BuyHold
4/23/2025The Goldman Sachs Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower TargetBuy$219.00 ➝ $197.00+63.72%
4/4/2025Argus
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeBuyHold
2/13/2025Scotiabank
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower TargetSector Outperform$244.00 ➝ $224.00+61.69%
2/13/2025BMO Capital Markets
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower TargetMarket Perform$156.00 ➝ $139.00+1.30%
2/13/2025Wells Fargo & Company
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower TargetEqual Weight$165.00 ➝ $140.00+4.40%
2/11/2025Bank Of America (Bofa)
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Lower TargetNeutral$178.00 ➝ $163.00+16.94%
2/11/2025Sanford C. Bernstein
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageMarket Perform$160.00+12.25%
1/13/2025William Blair
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Reiterated RatingOutperform
12/16/2024Stifel Nicolaus
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 DowngradeBuyHold$175.00+16.64%
12/10/2024Bank of America
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Reiterated RatingNeutral$178.00+13.77%
12/9/2024Jefferies Financial Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 DowngradeBuyHold$250.00 ➝ $180.00+14.08%
11/15/2024Wolfe Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoveragePeer Perform
10/31/2024Barclays
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Lower TargetEqual Weight$190.00 ➝ $180.00+2.18%
10/31/2024TD Cowen
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Lower TargetBuy$300.00 ➝ $275.00+56.24%
10/10/2024Raymond James Financial
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingMarket Perform
10/3/2024UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower TargetNeutral$234.00 ➝ $202.00+9.42%
9/9/2024Cantor Fitzgerald
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Reiterated RatingOverweight$292.00 ➝ $292.00+46.34%
1/7/2024BTIG Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingNeutral

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 03:26 AM ET.


Should I Buy Biogen Stock? BIIB Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Friday, September 12, 2025. Please send any questions or comments about these Biogen pros and cons to contact@marketbeat.com.

Biogen
Bull Case

green Wall Street bull icon

Here are some ways that investors could benefit from investing in Biogen Inc.:

  • Biogen Inc. recently reported strong quarterly earnings, with earnings per share significantly exceeding analysts' expectations, indicating robust financial health and operational efficiency.
  • The stock has a favorable price-to-earnings (P/E) ratio, suggesting that it may be undervalued compared to its earnings potential, which can attract value-focused investors.
  • Analysts have recently upgraded their ratings on Biogen Inc., with several firms raising their price targets, reflecting positive sentiment and potential for stock appreciation.
  • The current stock price is around $141, which is considered reasonable given the company's strong market position and growth prospects in the biotechnology sector.
  • Biogen Inc. has a solid market capitalization, indicating stability and the ability to invest in research and development for innovative therapies.

Biogen
Bear Case

red Wall Street bear icon

Investors should be bearish about investing in Biogen Inc. for these reasons:

  • Despite recent positive earnings, the stock has experienced fluctuations, which may indicate volatility and risk for investors looking for stable returns.
  • There is a significant percentage of institutional ownership, which can lead to less price stability as large investors may sell off shares quickly in response to market changes.
  • Biogen Inc. faces intense competition in the biotechnology field, which could impact its market share and profitability in the long term.
  • The company has a relatively low insider ownership percentage, which may raise concerns about alignment between management and shareholder interests.
  • Recent market trends show a cautious approach towards biotechnology stocks, which could affect investor sentiment and stock performance in the near term.

BIIB Forecast - Frequently Asked Questions

According to the research reports of 31 Wall Street equities research analysts, the average twelve-month stock price forecast for Biogen is $181.65, with a high forecast of $275.00 and a low forecast of $118.00.

31 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Biogen in the last twelve months. There are currently 21 hold ratings and 10 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" BIIB shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BIIB, but not buy additional shares or sell existing shares.

According to analysts, Biogen's stock has a predicted upside of 25.40% based on their 12-month stock forecasts.

Biogen has been rated by research analysts at Citigroup, HC Wainwright, Morgan Stanley, Needham & Company LLC, Piper Sandler, Royal Bank Of Canada, and Truist Financial in the past 90 days.

Analysts like Biogen less than other "medical" companies. The consensus rating for Biogen is Hold while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how BIIB compares to other companies.


This page (NASDAQ:BIIB) was last updated on 9/13/2025 by MarketBeat.com Staff
From Our Partners